Aptorum Group Limited - APM STOCK NEWS

Aptorum Group (NASDAQ: APM) announced that CEO Ian Huen has purchased 1,387,925 Class A Ordinary Shares at $2.882 each, a 10% premium over the last closing price. Huen emphasized the positive progress of the company's key programs, ALS-4 and SACT-1, during recent updates. With a focus on developing therapeutics for unmet medical needs, Aptorum continues to advance its clinical-stage pipeline and drug discovery platforms. The company is also partnering with Accelerate Technologies on a rapid pathogen detection technology.

Aptorum Group Limited (Nasdaq: APM) announced positive developments in its clinical trials. The Phase I trial for ALS-4, targeting Staphylococcus aureus, has completed initial cohorts with no serious adverse events reported. The study, which aims to evaluate ALS-4's safety and tolerability, is advancing to higher dosing cohorts. Additionally, Aptorum completed its Pre-IND meeting with the US FDA for SACT-1, a repurposed drug for neuroblastoma, and plans to submit an IND in Q3 2021. These advancements highlight Aptorum's commitment to addressing unmet medical needs.

Aptorum Group Limited (NASDAQ: APM) announced that President and Executive Director, Mr. Darren Lui, will present at the Benzinga Global Small Cap Conference on May 14, 2021, at 5:05 PM ET. The conference aims to highlight small-cap companies and their potential for growth and innovation. Aptorum Group focuses on developing therapeutics for severe medical needs, including oncology and infectious diseases. Their strategy includes drug discovery platforms and partnerships to enhance their product pipeline.

Aptorum Group (Nasdaq: APM) has partnered with Exeltis to develop a novel preclinical candidate targeting women's health issues, particularly endometriosis. The collaboration covers the European Union and Latin America, with potential expansion to the U.S. Aptorum retains development rights in other regions and aims to offer a non-hormonal treatment alternative for endometriosis, a condition affecting about 10% of women of reproductive age. The commercialization of this candidate is contingent upon regulatory approvals.

Aptorum Group Limited (Nasdaq: APM) announced an upcoming interview with President Darren Lui, to air on The RedChip Money Report on Bloomberg Network, April 24 at 7 p.m. ET. The show reaches 73 million households in the U.S., highlighting Aptorum's commitment to address unmet medical needs in oncology and infectious diseases. The company's pipeline includes drug discovery platforms and collaborations, notably with Accelerate Technologies for rapid pathogen detection diagnostics. For more details, visit www.aptorumgroup.com.

Aptorum Group Limited (Nasdaq: APM) has signed a material transfer and option agreement with Yale University to evaluate preclinical novel immunomodulators targeting autoimmune and oncology diseases. This collaboration includes a potential exclusive license to the associated intellectual property. Aptorum will assess these immunomodulators for various diseases, including lupus and arthritis, and may develop them further. CEO Ian Huen highlighted the initiative's potential to expand Aptorum's drug discovery capabilities, especially in treatments addressing cytokine storms related to COVID-19.

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) announced its 2020 financial results, reporting a net income of $4.9 million, a significant recovery from a net loss of $20.1 million in 2019. This turnaround was largely driven by a $25.2 million gain on marketable securities. The company's R&D expenses increased to $11.6 million due to advancements in project development. It remains focused on its clinical trials for ALS-4 and SACT-1, and plans to distribute a bioactive supplement in 2021. As of December 31, 2020, cash and restricted cash totaled $3.6 million, down from $5.3 million in 2019.

Aptorum Group Limited (Nasdaq: APM) has announced the dosing of its first human subject in a Phase I clinical trial for ALS-4, an orally-administered drug targeting infections from Staphylococcus aureus, including MRSA.

This randomized, double-blinded, placebo-controlled trial will enroll up to 72 healthy volunteers to assess the drug's safety and pharmacokinetics. ALS-4 employs a unique anti-virulence mechanism aimed at enhancing the efficacy of existing antibiotics. The Chief Medical Officer expressed optimism regarding ALS-4's potential in addressing high mortality rates associated with MRSA.

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) announced clearance from the Public Health Agency of Canada for its Clinical Trial Application (CTA) to initiate a Phase 1 study of ALS-4, a novel orally administered drug targeting infections from Staphylococcus aureus, including MRSA. This milestone marks a significant step for Aptorum as it transitions into a clinical-stage company. The trial aims to recruit 48 healthy volunteers for single-ascending doses and 24 for multiple-ascending doses, focusing on the safety, tolerability, and pharmacokinetics of ALS-4.